4D Molecular Therapeutics (FDMT) Other Gross PP&E Adjustments (2019 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with $13.1 million as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 16.08% to $13.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.1 million, a 16.08% increase, with the full-year FY2024 number at $12.4 million, down 34.67% from a year prior.
- Other Gross PP&E Adjustments was $13.1 million for Q3 2025 at 4D Molecular Therapeutics, down from $13.6 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $20.4 million in Q2 2024 to a low of $3.6 million in Q4 2021.
- A 5-year average of $13.5 million and a median of $13.3 million in 2025 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 331.75% in 2022, then tumbled 35.68% in 2024.
- 4D Molecular Therapeutics' Other Gross PP&E Adjustments stood at $3.6 million in 2021, then skyrocketed by 331.75% to $15.5 million in 2022, then increased by 22.49% to $18.9 million in 2023, then crashed by 34.67% to $12.4 million in 2024, then rose by 6.13% to $13.1 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Other Gross PP&E Adjustments are $13.1 million (Q3 2025), $13.6 million (Q2 2025), and $13.3 million (Q1 2025).